Man Group
CODX

Man Group’s Co-Diagnostics CODX Stock Holding History

Man Group’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-355
Closed -$11.9K – 2054
2024
Q1 		$11.9K Sell
355
-2,115
-86% -$76.6K ﹤0.01% 2097
2023
Q4 		$98.5K Buy
+2,470
New +$87.1K ﹤0.01% 1987
2023
Q3 		– Sell
-2,470
Closed -$93.3K – 1848
2023
Q2 		$82.2K Buy
+2,470
New +$94.5K ﹤0.01% 1894
2023
Q1 		– Sell
-1,731
Closed -$139K – 1985
2022
Q4 		$131K Buy
1,731
+30
+2% +$2.81K ﹤0.01% 1858
2022
Q3 		$164K Buy
+1,701
New +$238K ﹤0.01% 1799
2022
Q2 		– Sell
-1,514
Closed -$230K – 1671
2022
Q1 		$281K Buy
+1,514
New +$313K ﹤0.01% 1785

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Man Group's CODX Position: Q2 2024 in Review

Man Group sold out of Co-Diagnostics (CODX) in Q2 2024, closing a stake of 355 shares — an estimated $11.9K sold.

Man Group first reported a position in CODX in Q1 2022 and held it in 6 quarters. The position peaked at $281K in Q1 2022. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2024.

  • Man Group reported no remaining Co-Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Man Group sold 355 Co-Diagnostics shares in Q2 2024, an estimated $11.9K.
  • Man Group first reported a position in Co-Diagnostics in Q1 2022 and held it in 6 quarters.
  • Man Group's Co-Diagnostics position peaked at $281K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.